ArticleCancer medicine2025
Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and Body-Tail.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPancreatic cancer (PC) remains one of the most lethal malignancies worldwide, characterized by late-stage diagnosis and a poor prognosis. This study explores the clinical, biochemical, and gut microbiota differences between PC patients and healthy controls (CTRL), as well as between subgroups of PC patients with pancreatic head cancer (PHC) and pancreatic body-tail cancer (PBTC).
methodsA total of 72 PC patients and 37 CTRL subjects were included, with further stratification of PC patients into 45 PHC and 27 PBTC cases. Clinical and biochemical data were collected. Gut microbiota was analyzed by 16S rRNA gene sequencing. Alpha-diversity indices, Firmicutes/Bacteroidetes ratio and taxonomic composition were evaluated and compared in all the experimental group. Correlation analyses were performed between specific bacterial taxa and biochemical markers and a Random Forest algorithm was applied to identify taxa discriminating PC from CTRL and PHC from PBTC.
resultsClinical and biochemical data revealed significant heterogeneity between groups, with PHC patients exhibiting higher markers of inflammation and liver dysfunction, while PBTC patients showed relatively preserved physiological status. Gut microbiota analysis revealed significant dysbiosis in PC patients compared to CTRL. Alpha-diversity indices demonstrated reduced species evenness in PC patients, while the Firmicutes/Bacteroidetes ratio was significantly lower. Taxonomic composition analysis indicated enrichment of pro-inflammatory taxa and depletion of beneficial SCFA-producing genera. However, subgroup comparisons revealed distinct microbial profiles, with PHC patients enriched in taxa associated with localized inflammation and PBTCs showing higher levels of anti-inflammatory and SCFA-producing bacteria. A correlation analysis linked specific bacteria to markers of liver dysfunction and systemic inflammation, such as GGT, ALP, and ESR, while SCFA-producing taxa correlated negatively with inflammatory markers. A Random Forest algorithm identified key microbial taxa discriminating PC patients from CTRL and PHC from PBTC.
conclusionsThese findings highlight the interplay between microbiota composition, tumor localization, and systemic inflammation, showing a potential for microbiota-based diagnostics and interventions in PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.